The newly identified DPY30-ASH2L interface and ASH2L-NCP interface revealed in the current study provide a foundation for designing or screening inhibitors with high potency and specificity to target the “DPY30-ASH2L-MLL-NCP” axis, hopefully contributing to the discovery of new therapeutic drugs for certain cancers. Here, DPY30 is linked to cancer.